Business Description
Sanofi SA
SIC : 2834
ISIN : US80105N1054
Share Class Description:
LTS:0A2V: ADRCompare
Compare
Traded in other countries / regions
SAN.FranceSNY.USA0O59.UKSNW.BulgariaSNW.Germany1SAN.ItalySANO.AustriaSNY.Mexico IPO Date
2019-10-03Description
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.29 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.33 | |||||
| Debt-to-EBITDA | 2.2 | |||||
| Interest Coverage | 13.57 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2 | |||||
| Beneish M-Score | -2.54 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.6 | |||||
| 3-Year EBITDA Growth Rate | -10.9 | |||||
| 3-Year EPS without NRI Growth Rate | 2 | |||||
| 3-Year FCF Growth Rate | 10.8 | |||||
| 3-Year Book Growth Rate | 2.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 16.52 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 4.77 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 62.12 | |||||
| 14-Day RSI | 58.52 | |||||
| 12-1 Month Momentum % | 7.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1 | |||||
| Quick Ratio | 0.65 | |||||
| Cash Ratio | 0.23 | |||||
| Days Inventory | 249.68 | |||||
| Days Sales Outstanding | 64.77 | |||||
| Days Payable | 182.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 4.2 | |||||
| Shareholder Yield % | 4.25 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.91 | |||||
| Operating Margin % | 20.93 | |||||
| Net Margin % | 8.9 | |||||
| FCF Margin % | 8.8 | |||||
| ROE % | 5.77 | |||||
| ROA % | 3.31 | |||||
| ROIC % | 6.59 | |||||
| 3-Year ROIIC % | 16.5 | |||||
| ROC (Joel Greenblatt) % | 48.19 | |||||
| ROCE % | 6.33 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 28.19 | |||||
| Forward PE Ratio | 10.43 | |||||
| PE Ratio without NRI | 17.22 | |||||
| Shiller PE Ratio | 17.61 | |||||
| Price-to-Owner-Earnings | 14.24 | |||||
| PEG Ratio | 2.87 | |||||
| PS Ratio | 2.51 | |||||
| PB Ratio | 1.63 | |||||
| Price-to-Free-Cash-Flow | 28.77 | |||||
| Price-to-Operating-Cash-Flow | 14.66 | |||||
| EV-to-EBIT | 21.24 | |||||
| EV-to-Forward-EBIT | 11.53 | |||||
| EV-to-EBITDA | 12.58 | |||||
| EV-to-Forward-EBITDA | 9.48 | |||||
| EV-to-Revenue | 2.86 | |||||
| EV-to-Forward-Revenue | 2.63 | |||||
| EV-to-FCF | 32.8 | |||||
| Price-to-Projected-FCF | 0.94 | |||||
| Price-to-Median-PS-Value | 0.89 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.69 | |||||
| Price-to-Graham-Number | 16.33 | |||||
| Earnings Yield (Greenblatt) % | 4.71 | |||||
| FCF Yield % | 3.48 | |||||
| Forward Rate of Return (Yacktman) % | 11.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sanofi SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 51,370.11 | ||
| EPS (TTM) ($) | 1.819 | ||
| Beta | 0.89 | ||
| Volatility % | 25.14 | ||
| 14-Day RSI | 58.52 | ||
| 14-Day ATR ($) | 0.000026 | ||
| 20-Day SMA ($) | 49 | ||
| 12-1 Month Momentum % | 7.03 | ||
| 52-Week Range ($) | 45 - 52.77 | ||
| Shares Outstanding (Mil) | 2,507.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sanofi SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sanofi SA Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sanofi SA Frequently Asked Questions
What is Sanofi SA(LTS:0A2V)'s stock price today?
The current price of LTS:0A2V is $49.00. The 52 week high of LTS:0A2V is $52.77 and 52 week low is $45.00.
When is next earnings date of Sanofi SA(LTS:0A2V)?
The next earnings date of Sanofi SA(LTS:0A2V) is 2025-01-31 Est..
Does Sanofi SA(LTS:0A2V) pay dividends? If so, how much?
Sanofi SA(LTS:0A2V) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers